What does CUSIP 74019P108 represent in this 13F holders report?

CUSIP 74019P108 is the security identifier for DTIL - PRECISION BIOSCIENCES INC - COM used to aggregate holder disclosures.

How many institutions held DTIL - PRECISION BIOSCIENCES INC - COM in Q3 2023?

73 institutional investors reported DTIL - PRECISION BIOSCIENCES INC - COM for Q3 2023. Use the holders table for investor-level position and value details.

PRECISION BIOSCIENCES INC - COM (DTIL)

CUSIP: 74019P108

Q3 2023 13F Holders as of 30 Sep 2023

Security type / class: Equity / COM
Total 13F shares: 34,661,021
Total 13F value: $11,826,306
Share change: -8,880,144
Put/Call ratio: 0%
SEC-reported price per share: $0.34
Number of holders: 73
Value change: -$4,565,106
Number of buys: 31
Number of sells: 28

Security key

74019P108

Report period

Q3 2023

Institutions

Top holders

DTIL full security history Ownership snapshot Full 13F holder table PRECISION BIOSCIENCES INC SEC filings PRECISION BIOSCIENCES INC company facts

Broader feeds

Latest 13F filings Latest 13D/G filings Investors directory

Ownership snapshot

Top reported holders of DTIL - PRECISION BIOSCIENCES INC - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

NOVARTIS PHARMA AG

Disclosed value leader

NOVARTIS PHARMA AG

Comparable rows

0/15

Latest evidence

30 Jun 2023

3/4/5 13F Highest disclosed value: $4,590,753 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

NOVARTIS PHARMA AG has the largest disclosed position value at $4.59M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens NOVARTIS PHARMA AG's linked filing trail.

Disclosed position value Top 5

NOVARTIS PHARMA AG $4.59M

GREAT POINT PARTNERS LLC $3.93M

Capital World Investors $3.53M

VANGUARD GROUP INC $2.48M

ACADIAN ASSET MANAGEMENT LLC $1.53M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
NOVARTIS PHARMA AG	3/4/5 10%+ Owner 3/4/5	— denominator unverified	$4,590,753 12,407,440 shares	—	15 Jun 2022
GREAT POINT PARTNERS LLC	13F Company 13F	— denominator unverified	$3,929,081 7,469,736 shares	—	30 Jun 2023
Capital World Investors	13F Company 13F	— denominator unverified	$3,532,113 6,715,043 shares	—	30 Jun 2023
VANGUARD GROUP INC	13F Company 13F	— denominator unverified	$2,481,336 4,717,368 shares	—	30 Jun 2023
ACADIAN ASSET MANAGEMENT LLC	13F Company 13F	— denominator unverified	$1,527,000 2,905,818 shares	—	30 Jun 2023
Derek Jantz	3/4/5 Chief Scientific Officer, Director 3/4/5	— mixed-class rows	$1,509,439 4,079,565 shares mixed-class rows	—	07 Jun 2022

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2023

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions

34,661,021

Rows available

Investor	Option	Weight %	Change %	SEC-reported value	* Price	Shares	Share Change	Activity	Report Period

^* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2023 vs Q2 2023 Across Filers

Q2 2023 holders

Q3 2023 holders

Holder diff

-2

Investor	Q2 2023 Shares	Q3 2023 Shares	Share Diff	Share Chg %	Q2 2023 value	Q3 2023 value	Value change	Value Chg %